Device Trial Radar · NCT06611098
New Treatment of Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Feb 21, 2025
Primary completion
Nov 1, 2025
Study completion Feb 13, 2026
Sponsor
- Lead sponsor
- SymateseNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 24, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 35 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Osteoarthritis (OA) is a chronic degenerative joint disease characterized macroscopically by progressive damage of articular cartilage, joint space narrowing, subchondral bone remodelling, joint marginal osteophyte formation and synovitis. It is also characterized by a decrease of the concentration and molecular weight of the hyaluronic acid in the synovial fluid which ultimately leads to poor viscoelastic properties of synovial fluid and induction of proinflammatory pathways. The intra-articular injection of viscosupplementation gel (mainly exogenous hyaluronic acid) represents one of the most used therapeutic strategies to treat osteoarthritis symptoms. Several studies on knee Osteoarthritis, have shown that one or more weekly injection of viscosupplementation gel significantly relieves articular pain and ameliorates mobility and joint function for at least 6 months and more. Repeated courses of intra-articular injections are an effective and safe treatment for knee osteoarthritis symptoms. Based on studies conducted on intra-articular viscosupplementation gels, the most common side effects expected are local transient and short-lived adverse events such as pain, swelling and arthralgia in the site of administration, which are fully reversible in the days following the injection. Furthermore, such local effects may occur in a minority of cases and are usually treated conservatively with ice, non-steroidal anti-inflammatory drugs, and relative rest.
Conditions
- Knee Osteoarthristis
Interventions
ViscosupplementsDevice
intra-articular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the performance of ABIO3419 treatment versus the comparator in subjects at 3 months (V7) by assessing knee pain while walking on flat ground.Time frame: Month 3 after the last injection
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
IRIS CRO
Mtskheta, Georgia
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.